logo
How US aid cuts threaten care for HIV-infected patients in Uganda

How US aid cuts threaten care for HIV-infected patients in Uganda

Yahoo05-03-2025

At first glance, the two Ugandan women engaged in quiet conversation seem to have little in common.
However, beneath this surface lies a shared reality marked by profound challenges: both are grappling with the heavy burdens of widowhood, grief and are infected with HIV.
They are distressed over US President Donald Trump's recent announcement that the US will withhold international assistance, causing shock waves around the world.
Molly, 39 and the younger of the two women, is vital and energetic. She tells dpa, "When I heard about America suspending giving drugs to people with AIDS, I cried and said 'God save us'."
The US aid agency USAID is one of the largest aid agencies in the world, employing around 10,000 people, two-thirds of whom work outside the United States.
It is responsible for doling out much of the US government's humanitarian assistance to developing countries and countries in crisis. It is also a key donor to fund the medicines both women and other HIV-infected patients need.
"I am still crying because I had thought I would live longer. Now I am not sure it will happen," Molly says.
Her comments echo the panic and desperation among the hundreds of thousands people in this East African country who have the HIV virus.
Molly tested HIV-positive eight years ago. Since then, she has been taking antiretroviral (ARV) medication to keep the virus under control and her health stable.
So far, she has not developed the disease that can result from the virus without treatment, known as AIDS. She earns her living by selling fried bananas on the street in her home village. This is enough to make a very modest living, but not enough to buy medication privately.
ARV drugs are an important aid to survival
In Uganda alone, there are hundreds of thousands of patients living with HIV/AIDS. The disease is particularly widespread in the southern and eastern African regions.
However, while in the 1990s an HIV diagnosis was tantamount to a death sentence, patients who receive the necessary ARV medication are able to live with the disease.
Now, there is great concern in the countries affected by the US funding freeze that tens of thousands of people could be plunged into poverty.
"There is fear and panic among policy makers and people who have AIDS. The fear is that the ARVs are running out. Any disruption can cause problems," the head of the state-run Uganda AIDS Commission (UAC), Nelson Musoba, tells dpa.
Musoba says that due to the aid suspension, he urgently needs approximately $85 million to procure HIV/AIDS treatment drugs, laboratory testing equipment and patient monitoring.
Patients fear for their chances of survival
Molly's friend, 70-year-old Jane Francis Kannyange, also wonders how long she can survive without medication. The retired nurse has been HIV-positive since the late 1990s.
It was only when her husband died of AIDS-related causes in 2002 that she was given access to medication. The medication helped her to survive, but the 70-year-old is emaciated and frequently ill because her immune system is weakened.
After Trump's announcement, she says "my doctor called me and asked me 'how are you doing? Do you have enough drugs?'"
"He told me that the clinic where I get the drugs was closing down. I fainted soon after," Kannyange tells dpa.
Meanwhile, many of the health workers are now just as helpless as their patients.
A young doctor who worked at the Institute of Infectious Diseases in the Ugandan capital Kampala, which relied heavily on US funding to pay staff, says he lost his job following Trump's announcement.
"The announcement was very ... traumatic ... I am now on unpaid leave for 90 days. Without pay, I don't know how I'm going to look after my family, my children," the doctor told dpa on condition of anonymity.
The Trump administration's push to overhaul the development aid agency has placed nearly all employees of the agency worldwide on furlough and effectively halts most of the organization's operations.
Some 1,600 jobs are also being cut in the United States. Trump has claimed several times that USAID was being run by "radical lunatics" who were wasting taxpayers' money.
Successes in the fight against AIDS are now under threat
Uganda was one of the hardest-hit nations in the global AIDS crisis during the 1990s with an infection rate of about 30% at the time.
However, thanks to support from donors, the country embarked on a world-acclaimed ambitious AIDS control programme that brought infections down to the current 5%.
While 53,000 people in Uganda died from the deadly immunodeficiency disease and its consequences in 2010, this figure had fallen to 20,000 by 2023, according to the UAC.
Almost 1.5 million people in Uganda are living with the virus and around 1.3 million are receiving ARV medication.
But Musoba says that due to the funding freeze, there is a risk that the successes will be undone. "If the changes are not well-addressed, the achievements especially in the area of stigma control maybe reversed," Musoba tells dpa.
The Ugandan AIDS program, with an annual budget of $500 million, is 70% financed by US funds. According to the UAC, the US aid programme has not only supplied ARV drugs and HIV test kits but has also funded the salaries of over 4,300 Ugandan clinic staff and 16,000 community health workers.
Other African countries face cuts too
Uganda is not an isolated case. According to Médecins Sans Frontières (MSF), many health facilities in South Africa that relied on US-funded organizations for HIV programs - including testing, treatment and prevention - have been forced to shut down.
In Mozambique, a key MSF partner organization providing comprehensive HIV services had to cease operations entirely.
And in Zimbabwe, most organizations offering HIV programs have reportedly halted their work due to funding shortages and the inability to procure essential medicines. Other donors have been unable to fill the gaps quickly enough.
"The government is in urgent need of funds to offset the likely shortage and is quickly mobilizing resources," UAC boss Musoba says.
"We still need international assistance and we need to see how to manage the disruptions."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

My 5-year-old survived cancer twice. Medical innovation shouldn't be political.
My 5-year-old survived cancer twice. Medical innovation shouldn't be political.

Yahoo

time5 hours ago

  • Yahoo

My 5-year-old survived cancer twice. Medical innovation shouldn't be political.

Few issues in American politics have consistently united both parties like the fight against cancer. While funding levels and strategies may differ, Democrats and Republicans alike recognize that cancer doesn't discriminate – and neither should our commitment to defeat it. Under the Biden administration, the Cancer Moonshot was relaunched to accelerate progress toward a cure. More recently, President Donald Trump announced his 'Stargate' initiative, which aims to harness artificial intelligence in detecting and treating cancer, including through personalized mRNA vaccines. In the United States, cancer is the leading cause of death by disease for children after infancy. Across the political spectrum, there remains a shared hope: that no one should have to endure the pain of losing a loved one or fight this deadly disease. Yet today, that consensus is showing signs of strain. State legislatures across the country are advancing bills to ban or severely restrict the use of – and further research into – breakthrough technologies like mRNA, a technology that is driving promising advancements in cancer. What should be a story of American scientific innovation is being twisted into a political talking point. And it's putting lives at risk. Letters: Trump's anti-DEI mandate will make it hard to recruit new scientists If the politicians pushing these bans spent even a few minutes inside a pediatric oncology unit, maybe they'd understand. They'd see floors filled with sick children on small bicycles, pulling IV poles behind them. Children in hospital beds, brave beyond measure. And parents clinging to hope. I've seen it firsthand. I'm a mother whose 5-year-old daughter has survived cancer – twice. My daughter Charlie is one of a small percentage of pediatric cancer patients whose tumors don't show up on standard blood tests. Her cancer went undetected for more than a year. By the time doctors found it, it had already spread to her liver. She was just 3 years old and had Stage 4 cancer. Once Charlie's cancer was detected, we rushed into treatment: high-dose chemotherapy, stem cell transplants and multiple surgeries. After months of treatment, we got the news every parent prays for: Charlie was cancer-free. But just a few months later, scans revealed a relapse. Two small nodules were found on her lung. Her baby brother was only two months old when we learned her cancer had returned. Relapse treatment was grueling. Charlie lost weight and muscle mass. She needed a feeding tube to stay nourished, hydrated and medicated. But through it all, she never lost her smile. Her strength became ours. And while we juggled caring for a newborn and two other children, we held onto hope, because science gave us a reason to. Thanks to expert care at Seattle Children's and research-backed protocols, she's once again cancer-free. She started preschool this year. She's coloring, laughing and chasing her siblings again. Every option we had was made possible by decades of public investment in research. Families who came before us joined clinical trials. Lawmakers chose to fund pediatric science and cancer research. That is the same kind of work mRNA research builds on today. Researchers are developing an mRNA-based diagnostic test that could catch cancers like hers earlier, when they're more treatable. The test uses mRNA from her original tumor to detect any circulating cancer cells through a simple blood draw. Catching a relapse early could be lifesaving. We first learned about this test in 2023, and knowing it's almost within reach brings us, and families like ours, so much hope. Beyond mRNA-based diagnostic tests, mRNA has also shown early promise as a therapy for cancer patients, enabling personalized treatment that could more effectively target one's tumor. That kind of innovation is exactly what's under threat right now. The role of mRNA technology in oncology has been studied for decades, and yet some lawmakers want to roll this progress back, arguing it is untested and unsafe. This technology, along with many innovations that come from federally supported medical research, is a critical source of hope for families around the world. Opinion: Nurses are drowning while Braun ignores Indiana's health care crisis When you're watching your child battle cancer, every advancement matters. I know firsthand how critical it is to catch cancer early and have access to every possible treatment option. When politicians politicize science – when they ban or restrict it based on misinformation and politics – they aren't protecting families like mine. They're limiting our options. They're slowing down the breakthroughs that could save lives. We can't afford to let misinformation and polarized politics dictate the future of lifesaving research. Thanks to innovation in medical research, Charlie is thriving today, but far too many kids are still fighting. Let's ensure science continues to move forward for all of our children. Emily Stenson is a childhood cancer advocate and the mother of 5-year-old two-time cancer survivor Charlie Stenson. She lives in Seattle. This article originally appeared on USA TODAY: Cancer treatment breakthroughs using mRNA are under attack | Opinion

RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey

Yahoo

time7 hours ago

  • Yahoo

RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while maintaining a Sector Perform rating. This adjustment is based on insights from a 2022 patient survey, which assessed perceptions of lenacapavir among high-risk individuals on and off PrEP (pre-exposure prophylaxis), especially after phase 3 data release and in anticipation of its potential market launch. The firm's analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the potential for current PrEP users to switch to lenacapavir could all facilitate growth for Gilead Sciences, even with some cannibalization of its existing product called Descovy. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. In Q1 2025, Gilead Sciences reported total revenue of $6.67 billion, which was flat year-on-year and missed Street's estimates by 2.1%. Despite the revenue miss, Gilead reconfirmed its full-year revenue guidance at the midpoint of $28.4 billion, which is 1.1% below analysts' estimates. These results were driven by growth in the company's core HIV and liver disease segments, particularly from strong demand for Biktarvy and the ongoing launch of Libdelzi. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.

Historic Aussie-first breakthrough in fight against condition impacting 40 million
Historic Aussie-first breakthrough in fight against condition impacting 40 million

Yahoo

time19 hours ago

  • Yahoo

Historic Aussie-first breakthrough in fight against condition impacting 40 million

In a groundbreaking leap forward in the global fight against HIV, researchers at Melbourne's world-renowned Doherty Institute have developed a revolutionary method that could one day pave the way for a cure, using the same mRNA technology that powered COVID-19 vaccines. This discovery gives fresh hope to the nearly 40 million people around the world living with HIV. While today's treatments can keep the virus under control, they can't remove it completely. That's because HIV hides in a type of white blood cell, staying asleep and undetectable. But if treatment stops, the virus can wake up and spread again. For decades, this hidden "reservoir" has been one of the biggest obstacles to finding a cure. Now, researchers believe they've found a way to reach these sleeping cells and wake the virus up in a safe and controlled way, while the patient is still on their usual medication. Speaking to Yahoo News Australia, Dr Michael Roche, a Senior Research Fellow at the Doherty Institute, explained how his team used mRNA wrapped inside tiny fat-like bubbles called lipid nanoparticles. These nanoparticles are designed to travel directly to infected cells. Once inside, the mRNA sends instructions to the cell to make a protein called Tat — a natural HIV protein that tells the virus it's time to wake up. "Tat is a protein that helps the virus 'wake up' when the virus wants to," Dr Roche said. "Here we are using Tat to wake the virus up when we want to." This process is often called the "shock and kill" strategy. The idea is to force the virus out of hiding while the patient is still on HIV medication, so the virus can't spread and can instead be targeted and destroyed by the immune system or future therapies. The discovery is still in early stages, but it's the first time mRNA has successfully reached and activated the HIV reservoir in a lab setting. The team's next step is to test the treatment in animal models to check if it's safe and if it works. "We are looking for two signals," Dr Roche said. "Firstly, safety. Secondly, efficacy — whether it can wake up dormant HIV in animals." These trials will take a few years. Only after passing those tests can human trials begin — first to ensure the treatment is safe, and then to test how well it works in people. A key advantage is that this therapy uses the same technology that powered the COVID-19 vaccine rollout. "Our therapeutic is based on the same technology — mRNA and lipid nanoparticles — used in the COVID vaccines," Dr Roche said. "The global rollout of these vaccines has shown that this approach can be scaled and distributed globally." He pointed to a new BioNTech mRNA facility in Rwanda, which is being set up to support production in areas with a high burden of HIV. The team is also focused on making sure the treatment, if successful, can be made affordable and accessible. "We are committed to ensuring any cures we develop are scalable, accessible and affordable," Dr Roche said. Aussies warned over widespread danger emerging in homes Concerning roadside find reveals dangerous trend landing Aussies in hospital Controversial 'alcohol alternative' coming to Woolworths this month In Australia, around 29,000 people are living with HIV. New infections have dropped over the past decade thanks to wider access to HIV prevention medication (PrEP), regular testing, and strong treatment programs. The country recorded its lowest number of new HIV cases in over 20 years in 2022. But some challenges remain. In 2023, there was a slight increase in new cases, mostly among people born overseas and those infected through heterosexual contact. Still, the long-term trend is positive, and now, with this research, a cure no longer feels out of reach. If successful, this approach could one day mean people living with HIV no longer need daily medication, and may even be able to live completely free of the virus. As the world watches closely, Australia's scientists are once again leading the charge. Do you have a story tip? Email: newsroomau@ You can also follow us on Facebook, Instagram, TikTok, Twitter and YouTube.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store